MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Aeglea BioTherapeutics Net Income 2011-2026 | AGLE
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Aeglea BioTherapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -208 M | -339 M | -83.8 M | -65.8 M | -80.9 M | -78.3 M | -44.3 M | -27.2 M | -21.7 M | -11.3 M | -10.3 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.3 M | -339 M | -88.2 M |
Quarterly Net Income Aeglea BioTherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.2 M | -36.7 M | -44.8 M | - | -69 M | -38.8 M | -43.9 M | - | -40.1 M | -217 M | -18.4 M | - | -18.2 M | -22.3 M | -24.4 M | - | -20.3 M | -6.83 M | -18.2 M | -22.7 M | -18 M | -21.4 M | -18.7 M | -21.5 M | -21.6 M | -18 M | -17.2 M | -14.9 M | -11.9 M | -9.41 M | -8.12 M | -6.48 M | -7.87 M | -6.63 M | -6.25 M | -5.48 M | -6.24 M | -5.43 M | -4.55 M | -3.99 M | -3.41 M | -1.43 M | -2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.43 M | -217 M | -22.9 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
-33.4 M | $ 2.19 | 7.88 % | $ 123 M |  China |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K |  USA |
 |
BioLineRx Ltd.
BLRX
|
-27.1 M | $ 3.03 | 2.35 % | $ 908 M |  Israel |
 |
BioNTech SE
BNTX
|
10.3 B | $ 117.93 | -0.46 % | $ 27.2 B | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.31 | 1.22 % | $ 7.96 B |  Australia |
 |
BioXcel Therapeutics
BTAI
|
-59.6 M | $ 1.83 | 0.83 % | $ 4.64 M | USA |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 9.64 | -2.33 % | $ 1.58 B |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.88 M | $ 4.23 | 1.68 % | $ 9.2 B | Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
160 M | $ 26.09 | -0.21 % | $ 1.26 B | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Coherus BioSciences
CHRS
|
-238 M | $ 2.03 | 27.67 % | $ 191 M | USA |
 |
Aptose Biosciences
APTO
|
-25.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
-96.9 M | - | - | $ 269 M | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 230.76 | 0.92 % | $ 5 B |  Danmark |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.72 | 0.37 % | $ 17.1 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
141 M | $ 42.02 | 1.74 % | $ 4.34 B | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
164 M | $ 24.23 | -0.9 % | $ 2.87 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 70.82 | 1.77 % | $ 9.47 B | USA |
 |
Brickell Biotech
BBI
|
-5.69 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-645 M | - | 0.49 % | $ 251 B |  Cayman-islands |
|
Champions Oncology
CSBR
|
4.7 M | $ 6.9 | -0.43 % | $ 94.3 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-114 M | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-25 M | - | -9.72 % | $ 5.89 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
1.63 B | $ 171.66 | -1.23 % | $ 25 B | USA |
 |
Bio-Path Holdings
BPTH
|
-16.1 M | - | - | $ 100 K | USA |
 |
BioVie
BIVI
|
-17.5 M | $ 1.26 | 0.79 % | $ 1.86 M | USA |
 |
Baudax Bio
BXRX
|
-58.8 M | - | 0.59 % | $ 63 K | USA |